[Correspondence] B-cell targeted therapies in acute lymphocytic leukaemia

We read with interest Hagop Kantarjian and colleagues’ Seminar on acute lymphocytic leukaemia (ALL).1 Although the review focuses on the transformative impact of novel B-cell targeted therapies, several important considerations—such as infective adverse effects of bispecific T-cell engager (BiTE) therapy, and chimeric antigen receptor (CAR) T cells directed against B-cell surface antigens, potential use of immunoglobulin replacement therapy, and their wider impact on health-care systems—merit further discussion.